Nanobiotix announced that the FDA accepted a protocol amendment for its global Phase 3 NANORAY-312 study in head and neck cancer, submitted by Johnson & Johnson. The amendment removes the interim analysis and advances the final analysis to occur sooner with fewer events required. This change could accelerate the regulatory approval and commercialization of JNJ-1900 (NBTXR3), a novel cancer treatment activated by radiotherapy. Nanobiotix expects the final results to be available around the same time as the originally planned interim analysis, potentially enabling earlier revenue generation from milestone payments under its license agreement with Johnson & Johnson.
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) provides a more reliable and growing dividend income by holding companies with at least 25 years of consecutive dividend increases, unlike the SPDR S&P 500 ETF (SPY), which includes all S&P 500 co...
Johnson & Johnson announced that the Phase 3 MonumenTAL-3 study demonstrated that TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, significantly improved progression-free survival (up to 81.3%) and overall survival (up to...
A recent study by Spherix Global Insights highlights the unmet need for new treatments in warm autoimmune hemolytic anemia (w-AIHA), especially beyond second-line therapies where no clear standard exists. Current treatments rely heavily on corticoste...
Johnson & Johnson announced that its drug IMAAVY (nipocalimab-aahu) achieved a significant and durable hemoglobin response in patients with warm autoimmune hemolytic anemia (wAIHA) during a Phase 2/3 trial. Patients receiving the 30 mg/kg dose showed...
